

Maureen Coneys

April 12, 2006

Boston, MA

25 (Pages 94 to 97)

<p style="text-align: right;">94</p> <p>1 A. Strategies were developed to try to 2 negotiate with the providers that were needed. 3 Q. What were those strategies? 4 A. I don't remember them specifically, but it 5 was how the providers would be approached and who 6 would approach them and, you know, what the 7 alternatives were in the area if we couldn't get 8 particular providers to join the network. 9 Q. Was any consideration given to providing 10 additional amounts in reimbursement to incentivize 11 participation in the network? 12 A. I don't recall any discussion about 13 reimbursement. 14 Q. How long were you the executive director 15 for HMO Blue? 16 A. Until 1996, I believe. 17 Q. What position did you move to in 1996? 18 A. I became the deputy director of Blue Cross 19 Blue Shield of Massachusetts and New Hampshire, LLC. 20 Q. Let my pen catch up with that for a 21 second. There's a lot packed into that title. Can 22 you help me understand the various aspects of that?</p>	<p style="text-align: right;">96</p> <p>1 whether there were any opportunities to collaborate 2 on the administration of disease management and 3 other health management programs, you know, 4 purchasing kinds of discussions. I can't remember 5 any of the other things we looked at. 6 Q. What do you mean when you refer to 7 purchasing? 8 A. Supplies. 9 Q. Are you referring to gauzes, bandages, 10 things like that? 11 A. It would actually be more office supplies. 12 Q. Did that include drugs? 13 A. No. 14 Q. How many people were involved in that 15 collaborative effort? 16 A. Four. 17 Q. I take it one of them was the director? 18 A. Yes. 19 Q. And who were the two who worked below you? 20 A. There was another person who was at the 21 same level I was, Alan Rosenberg, and then there was 22 somebody who worked at the next level whose name was</p>
<p style="text-align: right;">95</p> <p>1 A. Yes. At that time Blue Cross of 2 Massachusetts and Blue Cross of New Hampshire had a 3 desire to work together to strengthen the regional 4 presence in the Blue Cross plans, and there was a 5 small group that was designated to work on what that 6 would look like, and I was one of those people. 7 Q. Was a particular entity created called 8 BCBS of Massachusetts and New Hampshire, LLC? 9 A. There was an LLC. The title was something 10 like what I described. 11 Q. What were the parameters under which the 12 two BCBS organizations wanted to work together? 13 A. Both plans would remain independent of one 14 another, but would collaborate on various activities 15 to improve our position in the marketplace or 16 improve our efficiency as organizations. 17 Q. Did any aspect of that collaboration 18 include the sharing of provider networks? 19 A. No. 20 Q. What sort of areas were encompassed by the 21 collaborative work? 22 A. Some of the health management programs,</p>	<p style="text-align: right;">97</p> <p>1 Sheila Buckley. 2 Q. Who was the person who was the director? 3 A. Sharon Smith. 4 Q. How long were you the deputy director of 5 that entity? 6 A. About a year and a half. 7 Q. Did the collaborative effort continue 8 beyond that? 9 A. No. 10 Q. So it lasted -- did it last in total for 11 that year-and-a-half time period? 12 A. Right. 13 Q. What was the conclusion of that 14 collaborative effort? 15 A. I don't know exactly what you mean. 16 Q. Were efforts at collaboration ended, or 17 were they made part of a different process? 18 A. They were made part of a different 19 process. 20 Q. And how was that change -- what was that 21 change structure? 22 A. I don't remember exactly how it was</p>

Maureen Coneys

April 12, 2006

Boston, MA

26 (Pages 98 to 101)

<p style="text-align: right;">98</p> <p>1 structured.</p> <p>2 Q. Was Ms. Smith the director of that effort</p> <p>3 throughout that time period?</p> <p>4 A. For the year and a half, yes.</p> <p>5 Q. In 1997, that ended in 1997, correct?</p> <p>6 A. I believe it was 1997.</p> <p>7 Q. Where did you -- what position did you</p> <p>8 move to then?</p> <p>9 A. Vice president for government programs.</p> <p>10 Q. How long did you hold that position?</p> <p>11 A. Until 2001.</p> <p>12 Q. 2001?</p> <p>13 A. Ah-hah.</p> <p>14 Q. What were the government programs that you</p> <p>15 were the vice president responsible for?</p> <p>16 A. Responsible for the company's contract</p> <p>17 with the Medicaid program and with federal</p> <p>18 government for its Bluecare 65 product.</p> <p>19 Q. Now what was the contract in relation to</p> <p>20 Medicaid?</p> <p>21 A. The Medicaid contracts with health plans</p> <p>22 to enroll Medicaid recipients into their health</p>	<p style="text-align: right;">100</p> <p>1 A. That's correct.</p> <p>2 Q. Now the amounts that BCBS of Massachusetts</p> <p>3 then reimbursed physicians who treated those</p> <p>4 patients, were those the same amounts that were</p> <p>5 reimbursed to physicians who were treating any other</p> <p>6 HMO Blue patient?</p> <p>7 A. I believe so.</p> <p>8 Q. So BCBS Massachusetts did not reimburse</p> <p>9 providers at the same rate as Medicaid would have</p> <p>10 reimbursed them had the patient had direct Medicaid</p> <p>11 coverage?</p> <p>12 A. Correct.</p> <p>13 MR. COCO: Objection.</p> <p>14 Q. Do you know what methodologies of Medicaid</p> <p>15 was used over time to reimburse providers in</p> <p>16 Massachusetts treating Medicaid patients?</p> <p>17 A. No.</p> <p>18 Q. Do you have an understanding what</p> <p>19 methodologies have been used at any time by Medicaid</p> <p>20 in Massachusetts?</p> <p>21 A. I believe they pay fee for service.</p> <p>22 Q. Do you know how the amounts in the fee for</p>
<p style="text-align: right;">99</p> <p>1 plans. For some period of time Blue Cross was a</p> <p>2 contracting health plan to Medicaid.</p> <p>3 Q. Now in those situations what amount was</p> <p>4 Medicaid paying to BCBS of Massachusetts in relation</p> <p>5 to Medicaid patients who had enrolled in its</p> <p>6 programs?</p> <p>7 A. I don't remember the amount we were paid.</p> <p>8 Q. How was it calculated?</p> <p>9 A. It was calculated based on a formula that</p> <p>10 the state, you know, used, and I don't remember the</p> <p>11 details of the formula.</p> <p>12 Q. Was it a capitated amount?</p> <p>13 A. Yes.</p> <p>14 Q. Were the Medicaid patients then enrolled</p> <p>15 in a specific BCBS of Massachusetts product, or did</p> <p>16 they have a choice of product?</p> <p>17 A. They were enrolled in HMO Blue.</p> <p>18 Q. Did the Medicaid patients have to pay</p> <p>19 premiums to BCBS Massachusetts?</p> <p>20 A. No.</p> <p>21 Q. So their entire payment was made by the</p> <p>22 Medicaid program to BCBS of Massachusetts?</p>	<p style="text-align: right;">101</p> <p>1 service schedule are calculated?</p> <p>2 A. No, I do not.</p> <p>3 Q. Or derived?</p> <p>4 A. No.</p> <p>5 Q. How long did BCBS Massachusetts have the</p> <p>6 Medicaid programs that we've been discussing?</p> <p>7 A. For several years, but I don't remember</p> <p>8 the exact time line.</p> <p>9 Q. Did the program start when you became VP</p> <p>10 for government programs, or did they already exist?</p> <p>11 A. They already existed.</p> <p>12 Q. Were the programs concluded, terminated</p> <p>13 during your tenure as the VP for government</p> <p>14 programs?</p> <p>15 A. Yes.</p> <p>16 Q. Some time in '97 to 2001?</p> <p>17 A. Yes.</p> <p>18 Q. Do you know when approximately?</p> <p>19 A. I don't remember when.</p> <p>20 Q. Now the BC65 product, that was a similar</p> <p>21 product on the Medicare side, correct?</p> <p>22 A. It was a --</p>

Maureen Coneys

April 12, 2006

Boston, MA

27 (Pages 102 to 105)

<p style="text-align: right;">102</p> <p>1 MR. COCO: Objection.</p> <p>2 A. It was a contract with the what's now</p> <p>3 called CMS.</p> <p>4 Q. Now CMS would then pay BCBS of</p> <p>5 Massachusetts a capitated amount, correct?</p> <p>6 A. Correct.</p> <p>7 Q. And BCBS Massachusetts would then enroll</p> <p>8 patients in its own product?</p> <p>9 A. That's correct.</p> <p>10 Q. Now in this case those patients were</p> <p>11 enrolled in a specific product, correct?</p> <p>12 A. Yes.</p> <p>13 Q. And that product was the BC65 product?</p> <p>14 A. Yes.</p> <p>15 Q. That's a product unique to Medicare</p> <p>16 patients?</p> <p>17 A. Yes.</p> <p>18 Q. Managed Medicare?</p> <p>19 A. Yes.</p> <p>20 Q. Now during this time period '97 to 2001,</p> <p>21 what were you doing on a day-to-day basis in</p> <p>22 relation to these two programs?</p>	<p style="text-align: right;">104</p> <p>1 the financial, you know, plan for Bluecare 65.</p> <p>2 Maintaining the network.</p> <p>3 Q. Now we'll come back to BC65 in a little</p> <p>4 while. Let me ask you a bit more about the Medicaid</p> <p>5 product.</p> <p>6 Why did BCBS of Massachusetts decide to</p> <p>7 stop participating in that program or to cease</p> <p>8 contracting with the government to treat Medicaid</p> <p>9 patients?</p> <p>10 A. Blue Cross was losing money on the</p> <p>11 contract, and the state was in the process of</p> <p>12 rolling out a new program that was going to require</p> <p>13 the health plan to manage more complex categories of</p> <p>14 Medicaid recipients, and the health plan didn't have</p> <p>15 really the resources and skillset to manage the new</p> <p>16 populations that the state was asking to be part of</p> <p>17 the program, so the company had to make a decision</p> <p>18 whether it wanted to, you know, secure additional</p> <p>19 resources and expertise or whether it wanted to not</p> <p>20 continue to be part of the program, and the company</p> <p>21 made the decision not to continue.</p> <p>22 Q. Was the financial problem the fact that</p>
<p style="text-align: right;">103</p> <p>1 A. Evaluating, again, the benefit design. It</p> <p>2 was different for Medicaid than it was for Bluecare</p> <p>3 65.</p> <p>4 Q. Let's take them one by one. Let's start</p> <p>5 with Medicaid.</p> <p>6 A. For Medicaid it was making sure that we</p> <p>7 were in compliance with the contract requirements</p> <p>8 with the state, and I actually spent most of the</p> <p>9 time that I dealt with Medicaid evaluating an RFP</p> <p>10 that they were issuing for a new program and whether</p> <p>11 Blue Cross would continue to participate in the</p> <p>12 Medicaid program under this new contract that</p> <p>13 Medicaid was offering.</p> <p>14 Q. Anything else?</p> <p>15 A. No.</p> <p>16 Q. How about in relation to the BC65 product?</p> <p>17 A. For Bluecare 65 I was responsible for the</p> <p>18 product design, the operations area and the claims</p> <p>19 processing enrollment, grievance area for Bluecare</p> <p>20 65. I was also responsible for compliance,</p> <p>21 responsible for working on what the supplemental</p> <p>22 premium would be that we would charge in determining</p>	<p style="text-align: right;">105</p> <p>1 the capitated payments that were offered were set at</p> <p>2 a rate that was too low?</p> <p>3 A. Yes.</p> <p>4 Q. Were there any other aspects of the</p> <p>5 financial arrangement that contributed to this being</p> <p>6 an option that BCBS Massachusetts decided not to</p> <p>7 pursue?</p> <p>8 A. Not related to the financial arrangement.</p> <p>9 Q. Now from the perspective of an individual</p> <p>10 Medicaid patient, how would his options differ if he</p> <p>11 enrolled in Medicaid directly versus through BCBS of</p> <p>12 Massachusetts?</p> <p>13 MR. COCO: Objection.</p> <p>14 A. I don't remember.</p> <p>15 Q. Would a patient's financial obligations in</p> <p>16 terms of co-payments or co-insurance obligations,</p> <p>17 vary depending on whether they enrolled through BCBS</p> <p>18 of Massachusetts or directly with Medicaid?</p> <p>19 A. I don't remember.</p> <p>20 Q. In 2001 did your position change?</p> <p>21 A. Yes, it did.</p> <p>22 Q. What did you move to in 2001?</p>

Maureen Coneys

April 12, 2006

Boston, MA

28 (Pages 106 to 109)

<p style="text-align: right;">106</p> <p>1 A. I became the senior vice president for 2 health care quality and cost. 3 MR. COCO: That sounds like you're about 4 to get into another category. We've been going 5 about an hour. 6 MR. MANGI: Sure. Let me cover a quick 7 question and then we'll be done. 8 Q. How long did you hold that position? 9 A. I still hold that position. 10 Q. Have you held that position continuously 11 from 2001 to the present? 12 A. Yes. 13 MR. MANGI: All right, let's take a break. 14 (Brief Recess.) 15 Q. Miss Coneys, I'd like to ask you a few 16 more questions about the staff model HMO for BCBS 17 Massachusetts. I believe you testified earlier that 18 some of the patients who were treated at the 19 community health centers were originally enrolled in 20 products that provided that their treatment would be 21 at such sites, right? 22 A. Correct.</p>	<p style="text-align: right;">108</p> <p>1 Q. They were cash-paying patients? 2 A. Yes. 3 Q. In relation to the patients who had their 4 insurance from different health insurers other than 5 BCBS of Massachusetts, how was the amount of 6 reimbursement to the Medical East Medical West 7 facilities determined? 8 MR. COCO: Objection. 9 A. I don't know. 10 Q. Do you know whether those other health 11 insurers contracted directly with the community 12 health centers, or did they contract with BCBS of 13 Massachusetts to allow access to all the community 14 health centers? 15 A. I don't know. 16 Q. Do you know what methodologies were 17 utilized to reimburse the staff model HMO sites for 18 services rendered with drugs administered to those 19 members of other insurance companies? 20 A. I don't know. 21 Q. How about the cash-paying customers? How 22 were the amounts that they were charged determined?</p>
<p style="text-align: right;">107</p> <p>1 Q. And later on they were enrolled in HMO 2 Blue which included the staff model sites as one 3 option among different sites? 4 A. That's right. 5 Q. Other than those patients who came to the 6 staff model facilities through those products, I 7 believe you mentioned that there were also patients 8 treated at those health centers who got their health 9 insurance through other health insurance companies, 10 is that correct? 11 A. That wasn't always the case, but in the 12 later years that Blue Cross owned the health centers 13 that was true. 14 Q. Do you have a sense as to what time period 15 that was? 16 A. It was after HMO Blue was developed. 17 Q. That's after '91? 18 A. After '92 actually. 19 Q. In addition to those patients were there 20 patients who came in for treatment to the staff 21 model HMO sites that had no health insurance? 22 A. Yes.</p>	<p style="text-align: right;">109</p> <p>1 A. It was a fee schedule. 2 Q. Was there a fee schedule specific to 3 services and others specific to drugs that they may 4 be administered in the course of a visit? 5 A. I don't remember. 6 Q. Do you know how the amounts of those fee 7 schedules were calculated? 8 A. I don't. 9 Q. Do you know whether the amounts on those 10 fee schedules were intended to equal the costs to 11 the facility of providing those services or 12 acquiring those drugs, or did they also incorporate 13 an element of margin? 14 A. I don't know. 15 Q. Between the time period that you were 16 executive director of the Braintree site, were there 17 cash-paying customers being treated at that 18 facility? 19 A. Yes. 20 Q. Was it your expectation that your site, 21 that had some profitability issues, would be 22 charging those patients an amount exactly equal to</p>

Maureen Coneys

April 12, 2006

Boston, MA

29 (Pages 110 to 113)

<p style="text-align: right;">110</p> <p>1 the cost of rendering services and administering</p> <p>2 drugs to them?</p> <p>3 MR. COCO: Objection.</p> <p>4 A. I don't remember.</p> <p>5 Q. Did you have an expectation one way or the</p> <p>6 other in terms of whether you would bill them purely</p> <p>7 at cost for everything or at some amount higher than</p> <p>8 cost?</p> <p>9 A. I don't remember ever having any</p> <p>10 discussions around that.</p> <p>11 Q. Did you have an expectation one way or the</p> <p>12 other?</p> <p>13 A. I did not.</p> <p>14 Q. The fee schedules that determined how much</p> <p>15 was paid by a cash-paying customer, were those,</p> <p>16 during the time you were executive director of the</p> <p>17 Braintree site, maintained in paper format?</p> <p>18 A. I don't remember ever seeing the fee</p> <p>19 schedule in paper or otherwise.</p> <p>20 Q. The time period -- but you're aware that</p> <p>21 those fee schedules did exist, correct?</p> <p>22 A. Right.</p>	<p style="text-align: right;">112</p> <p>1 Q. Sure. If I were to look through the files</p> <p>2 of the Braintree site or other staff model HMO sites</p> <p>3 and came across fee schedules, would those be fee</p> <p>4 schedules determining the amounts that would be paid</p> <p>5 by these cash-paying patients, the uninsured</p> <p>6 patients who would come in off the street, or could</p> <p>7 these fee schedules relate to something else?</p> <p>8 MR. COCO: Objection.</p> <p>9 A. I don't know.</p> <p>10 Q. Well, would there be any other fee</p> <p>11 schedules that you are aware of other than the fee</p> <p>12 schedules we've discussed relating to cash-paying</p> <p>13 patients?</p> <p>14 A. There are none that I'm aware of.</p> <p>15 MR. COCO: Objection.</p> <p>16 Q. Now in 2001 you came to your current</p> <p>17 position which is VP for health care quality and</p> <p>18 cost?</p> <p>19 A. Correct.</p> <p>20 Q. Is it just cost or cost containment?</p> <p>21 A. Just cost.</p> <p>22 Q. What are your responsibilities in this</p>
<p style="text-align: right;">111</p> <p>1 Q. During the time period that you were</p> <p>2 executive director of the Braintree site, was there</p> <p>3 any sort of electronic technology utilized at the</p> <p>4 site such that could have housed fee schedules?</p> <p>5 A. There were computers that were used.</p> <p>6 Q. Do you have any understanding as to</p> <p>7 whether or not fee schedules in that late '80's,</p> <p>8 early '90's period, were maintained on computers?</p> <p>9 A. I don't know.</p> <p>10 Q. Did the staff model facilities maintain</p> <p>11 any fee schedules other than the ones used in</p> <p>12 determining the amounts that would be paid by cash</p> <p>13 off-the-street uninsured patients?</p> <p>14 A. No.</p> <p>15 Q. So if one were to look through files of</p> <p>16 staff model HMO's, one came across fee schedules,</p> <p>17 they would be specific to these cash-paying</p> <p>18 uninsured patients and the amounts they were</p> <p>19 charged?</p> <p>20 MR. COCO: Objection.</p> <p>21 Q. Is that accurate?</p> <p>22 A. Could you say it again?</p>	<p style="text-align: right;">113</p> <p>1 position?</p> <p>2 A. I'm responsible for the company's health</p> <p>3 care quality strategy and programs and the company's</p> <p>4 health management and utilization management</p> <p>5 programs.</p> <p>6 Q. Anything else?</p> <p>7 A. No. Under the quality area I am</p> <p>8 responsible for all the accreditation activities for</p> <p>9 the various entities that accredit health plans.</p> <p>10 Q. So accreditation of health plans or</p> <p>11 physicians?</p> <p>12 A. Health plans.</p> <p>13 Q. What sort of entities provide</p> <p>14 accreditation to health plans?</p> <p>15 A. National Committee on Quality Assurance,</p> <p>16 NCQA.</p> <p>17 Q. Now have your responsibilities changed in</p> <p>18 any way between 2001 and 2006?</p> <p>19 A. Not really.</p> <p>20 Q. I'd like to talk first about the health</p> <p>21 care quality aspect of your role. Other than</p> <p>22 accreditation of BCBS of Massachusetts, what other</p>

Maureen Coneys

April 12, 2006

Boston, MA

30 (Pages 114 to 117)

<p style="text-align: right;">114</p> <p>1 issues do you deal with in relation to health care</p> <p>2 and quality and strategies?</p> <p>3 A. I deal with the evaluation of quality</p> <p>4 metrics that are used in the industry and how they</p> <p>5 should be applied in Blue Cross Blue Shield of</p> <p>6 Massachusetts programs. I also deal with a hospital</p> <p>7 quality reimbursement program as part of our</p> <p>8 contracts with the hospitals in the state, and I'm</p> <p>9 responsible for the company's peer review activity,</p> <p>10 patient care assessment activity.</p> <p>11 Q. Anything else?</p> <p>12 A. I think that's pretty much it.</p> <p>13 Q. What do you mean when you refer to quality</p> <p>14 metrics?</p> <p>15 A. There are various nationally industry</p> <p>16 recognized ways in which the industry measures the</p> <p>17 quality of care that patients receive in the health</p> <p>18 care system, and my area is responsible for</p> <p>19 evaluating those metrics and deciding how we can use</p> <p>20 those measurement systems and metrics to help</p> <p>21 promote and improve quality of care in the health</p> <p>22 care system.</p>	<p style="text-align: right;">116</p> <p>1 with hospitals, we include in that an incentive</p> <p>2 program where they can earn additional money from us</p> <p>3 if they achieve agreed upon improvements in quality</p> <p>4 metrics.</p> <p>5 Q. Is this the same quality metrics we've</p> <p>6 just been discussing?</p> <p>7 A. They are some of them, yes.</p> <p>8 Q. Other than your assessment of your work in</p> <p>9 relation to hospital incentive programs, do you play</p> <p>10 any role in hospital contracting?</p> <p>11 A. No.</p> <p>12 Q. Are you familiar with Medicaid shortfall</p> <p>13 payments or government shortfall payments?</p> <p>14 A. Only in hearing them as a general topic in</p> <p>15 the company.</p> <p>16 Q. What's your understanding as to what those</p> <p>17 are?</p> <p>18 A. Payments that the hospitals look to us for</p> <p>19 to make up for the money they're not getting from</p> <p>20 Medicaid.</p> <p>21 Q. If a hospital is not getting a sufficient</p> <p>22 amount of reimbursement from Medicaid, how does that</p>
<p style="text-align: right;">115</p> <p>1 Q. Is quality of care assessed through</p> <p>2 service of patient satisfaction?</p> <p>3 A. That's one method.</p> <p>4 Q. What other methods do you utilize?</p> <p>5 A. Through claims.</p> <p>6 Q. I'm sorry?</p> <p>7 A. Through claims.</p> <p>8 Q. Through claims? How do claims provide</p> <p>9 information about quality of care?</p> <p>10 A. We can use claims to determine if patients</p> <p>11 are receiving the treatments and tests and care</p> <p>12 that's suggested based on the conditions they have.</p> <p>13 We also can identify where there have been</p> <p>14 complications from procedures that were done from</p> <p>15 claims.</p> <p>16 Q. After quality metrics the second aspect of</p> <p>17 the quality you earlier mentioned is hospital</p> <p>18 quality. I believe you said reimbursement programs?</p> <p>19 A. Incentive program. That's --</p> <p>20 Q. What are those?</p> <p>21 A. That's part of our -- when we contract</p> <p>22 with hospitals and negotiate our reimbursement terms</p>	<p style="text-align: right;">117</p> <p>1 involve the BCBS of Massachusetts?</p> <p>2 A. I don't know.</p> <p>3 MR. COCO: Objection.</p> <p>4 Q. Have you gained, at any point, any</p> <p>5 understanding as to why BCBS Massachusetts makes</p> <p>6 these payments?</p> <p>7 A. No.</p> <p>8 Q. Do you have any idea as to why it makes</p> <p>9 the payments?</p> <p>10 A. No.</p> <p>11 Q. Is it your understanding that those</p> <p>12 payments are made on a regular basis to hospitals?</p> <p>13 A. I don't know how they're made.</p> <p>14 Q. Are you aware if Medicaid shortfall</p> <p>15 payments only as a concept, or do you know whether</p> <p>16 or not they've actually been implemented and</p> <p>17 applied?</p> <p>18 A. I'm aware of them as a concept.</p> <p>19 MR. COCO: Objection.</p> <p>20 Q. Who's responsible for handling Medicaid</p> <p>21 shortfall payments at BCBS of Massachusetts?</p> <p>22 MR. COCO: Objection.</p>

Maureen Coneys

April 12, 2006

Boston, MA

31 (Pages 118 to 121)

<p style="text-align: right;">118</p> <p>1 A. I'm not sure there's anybody who owns 2 Medicare shortfall payments at Blue Cross Blue 3 Shield of Massachusetts. 4 Q. Who's in charge of the hospital contract? 5 A. Deb Devaux. 6 Q. Are you familiar with the fact that BCBS 7 of Massachusetts is in the process of changing its 8 methodology for reimbursing hospital outpatient 9 departments for drugs administered to its members? 10 A. No, I'm not. 11 Q. Are you aware of the fact that BCBS 12 Massachusetts is moving that setting from a 13 percentage of charge-based methodology to the AWP- 14 based methodology? 15 A. I'm not aware of that. 16 Q. Are you familiar with the term percentage 17 of charge? 18 A. Yes. 19 Q. What's your understanding as to what that 20 means as a reimbursement methodology? 21 A. It means that we pay a percent of what the 22 charge is.</p>	<p style="text-align: right;">120</p> <p>1 Q. Did you ever hear AWP referred to as ain't 2 what's paid? 3 A. No. 4 Q. Have you ever heard that term before 5 today? 6 A. No. 7 Q. After your time at Bay State did you ever, 8 in the course of your work in the industry, have 9 occasion to gain an understanding of average 10 wholesale price beyond what the acronym stands for? 11 A. No. 12 Q. Now I'd like to ask you about the NM3 13 committee. Are you familiar with that? 14 A. Yes, I am. 15 Q. What does NM3 stand for? 16 A. It stands for new medical management 17 model. Steering committee. The NM3 is new medical 18 management model steering committee. 19 Q. What does that committee do? 20 A. It evaluates health management program 21 opportunities and evaluates business cases around 22 new programs and existing programs and makes</p>
<p style="text-align: right;">119</p> <p>1 Q. What's the charge? 2 A. Whatever the provider charges for service. 3 Q. In the course of your tenure in the 4 industry, when's the first time you heard of the 5 term, AWP? 6 A. When I worked for Bay State Health Care. 7 Q. And what was the time period on that? 8 A. That was 1979 to 1987. 9 Q. In what context during your time at Bay 10 State did you have occasion to deal with average 11 wholesale price or AWP? 12 A. I actually never dealt directly with AWP 13 or the concept of it. I heard it as a term while I 14 was at Bay State. 15 Q. Do you recall the circumstances in which 16 you heard the term being used? 17 A. It was related to Bay State's prescription 18 drug program. 19 Q. Did you gain an understanding at that time 20 of what AWP meant or what it was? 21 A. I only gained an understanding of what the 22 initials stand for.</p>	<p style="text-align: right;">121</p> <p>1 decisions as to whether the company should invest in 2 the development or acquisition of programs. 3 Q. How long has the NM3 committee been in 4 existence? 5 A. Since probably 2001, 2002. 6 Q. Have you been a member of that committee 7 since its inception? 8 A. Yes. 9 Q. Remain a member of that committee today? 10 A. Yes. 11 Q. What sort of issues has the NM3 committee 12 dealt with over time? 13 A. It has dealt with the development of 14 disease management programs for diabetes or coronary 15 artery disease, for rare diseases, for depression. 16 It has looked at a Blue Health coach program. 17 It has also dealt with a radiology 18 management program. It has looked at some 19 chiropractic utilization issues. 20 Q. Do you recall the NM3 committee dealing 21 with the issue of implementing specialty pharmacy 22 programs?</p>

Maureen Coneys

April 12, 2006

Boston, MA

32 (Pages 122 to 125)

<p style="text-align: right;">122</p> <p>1 A. Yes.</p> <p>2 Q. Let's turn to a document.</p> <p>3 MR. MANGI: Mark this as Exhibit Coneys</p> <p>4 001 to the deposition.</p> <p>5 (Overview of Specialty Pharmacy</p> <p>6 marked Exhibit Coneys 001.)</p> <p>7 Q. Would you please take a moment to</p> <p>8 familiarize yourself with that document, and let me</p> <p>9 know when you're ready.</p> <p>10 Have you ever seen the document marked as</p> <p>11 Exhibit Coneys 001 before?</p> <p>12 A. I don't remember specifically seeing the</p> <p>13 document before.</p> <p>14 Q. Is the content of the document familiar?</p> <p>15 A. Yes.</p> <p>16 Q. Did you participate in the consideration</p> <p>17 of the NM3 committee regarding whether or not</p> <p>18 specialty pharmacy programs should be implemented</p> <p>19 and if so, what the parameters of those programs</p> <p>20 should be?</p> <p>21 A. Yes, I did.</p> <p>22 Q. When was this issue first brought up at</p>	<p style="text-align: right;">124</p> <p>1 the group on what specialty pharmacy services were</p> <p>2 which is what some of what's in here looks like it</p> <p>3 may have been doing, and analyzing how much the</p> <p>4 company is spending on specialty pharmacy services</p> <p>5 and discussions around how specialty pharmacy is</p> <p>6 generally handled in the industry and what options</p> <p>7 are around how health plans tend to handle specialty</p> <p>8 pharmacy services.</p> <p>9 Q. What were the options that were being</p> <p>10 discussed?</p> <p>11 A. Contracting with particular vendors to</p> <p>12 provide, you know, exclusive or whatever basis</p> <p>13 specialty pharmacy services on behalf of our</p> <p>14 members.</p> <p>15 Q. What analysis was done around these</p> <p>16 issues?</p> <p>17 A. How much we're spending for different</p> <p>18 categories of specialty drugs and I believe there</p> <p>19 was some benchmarking of industry activities around</p> <p>20 who contracts with various vendors and so forth.</p> <p>21 Q. Who's responsible for performing that</p> <p>22 analysis?</p>
<p style="text-align: right;">123</p> <p>1 BCBS of Massachusetts?</p> <p>2 A. I don't remember specifically, but it was</p> <p>3 a couple of years ago, I believe.</p> <p>4 Q. Do you recall who first raised the issue?</p> <p>5 A. I don't specifically remember who raised</p> <p>6 it.</p> <p>7 Q. Logistically what were the steps that the</p> <p>8 committee went through in considering this issue?</p> <p>9 A. I'm sorry.</p> <p>10 Q. Let me clarify the question. Was the NM3</p> <p>11 committee the group tasked with considering whether</p> <p>12 or not to implement a specialty pharmacy program?</p> <p>13 A. Initially, yes.</p> <p>14 Q. Over what period of time did the NM3</p> <p>15 committee consider that issue?</p> <p>16 A. I don't remember the specific dates, but</p> <p>17 it was over a several-month period.</p> <p>18 Q. Can you describe for me logistically what</p> <p>19 work or analysis was being done in relation to</p> <p>20 specialty pharmacies during that period of some</p> <p>21 months?</p> <p>22 A. The part of the work involved educating</p>	<p style="text-align: right;">125</p> <p>1 A. The analysis was performed jointly by our</p> <p>2 actuarial department and our ancillary provider</p> <p>3 contracting area.</p> <p>4 Q. Do you recall the names of any of the</p> <p>5 individuals who were involved in that analysis?</p> <p>6 A. John Killion from our provider contracting</p> <p>7 area, and I don't remember specifically which of the</p> <p>8 actuarial people were involved.</p> <p>9 Q. Do you recall what was analyzed around the</p> <p>10 issue of what's being spent and benchmarking?</p> <p>11 A. I don't understand.</p> <p>12 MR. COCO: Objection.</p> <p>13 Q. In terms of the analysis, you described it</p> <p>14 as is encompassing number one, how much was being</p> <p>15 spent, two, analysis around benchmarking and three,</p> <p>16 the issue of who people in the industry are</p> <p>17 contracting with. Did I write that down correctly?</p> <p>18 A. You did.</p> <p>19 Q. My question is in relation to the first</p> <p>20 two issues; how much is being spent and around the</p> <p>21 issue of benchmarking. What, specifically, was</p> <p>22 being analyzed?</p>

Maureen Coneys

April 12, 2006

Boston, MA

33 (Pages 126 to 129)

<p style="text-align: right;">126</p> <p>1 MR. COCO: Objection.</p> <p>2 A. How much was being spent, we were</p> <p>3 analyzing for specialty drugs that are considered to</p> <p>4 be specialty drugs. How much we spend as a health</p> <p>5 plan both in aggregate and on per member basis.</p> <p>6 Q. By spent, are you referring though to the</p> <p>7 amounts that are reimbursed to the health care</p> <p>8 providers who administer those drugs to members?</p> <p>9 A. Yes.</p> <p>10 Q. And what are you referring to when you</p> <p>11 talk about benchmarking?</p> <p>12 A. Looking at how other plans in the industry</p> <p>13 are providing these services, whether they're</p> <p>14 contracting on an exclusive basis with a vendor or</p> <p>15 multiple vendors or how they're providing the</p> <p>16 services.</p> <p>17 Q. Was any analysis performed of the amounts</p> <p>18 that were currently being spent reimbursing</p> <p>19 providers for specialty drugs versus the amount that</p> <p>20 would be spent under a specialty pharmacy program?</p> <p>21 A. Yes.</p> <p>22 Q. Do you recall who performed that analysis?</p>	<p style="text-align: right;">128</p> <p>1 Q. Do you recall what the conclusions were of</p> <p>2 that analysis in relation to oncology drugs?</p> <p>3 A. I do not.</p> <p>4 Q. Do you recall whether the analysis</p> <p>5 revealed the potential net savings?</p> <p>6 A. Yes, it did.</p> <p>7 Q. Do you recall whether that potential net</p> <p>8 savings on annualized basis was hundreds of dollars,</p> <p>9 thousands of dollars, millions of dollars?</p> <p>10 A. I don't recall.</p> <p>11 Q. Do you maintain copies of any of this</p> <p>12 financial analysis around the specialty pharmacy</p> <p>13 issue in your files?</p> <p>14 A. I do not.</p> <p>15 MR. MANGI: For the record, would call for</p> <p>16 the production of the analysis that's been the</p> <p>17 subject of this testimony pertaining to specialty</p> <p>18 pharmacy products and contemplation of potential</p> <p>19 savings.</p> <p>20 MR. COCO: And we request that you put</p> <p>21 that request in a separate letter.</p> <p>22 MR. MANGI: While we're on the topic, I'll</p>
<p style="text-align: right;">127</p> <p>1 A. I believe again it was performed by</p> <p>2 actuarial in conjunction with John Killion's area.</p> <p>3 Q. Do you recall what the conclusions were of</p> <p>4 that analysis?</p> <p>5 A. That there were potential savings, but I</p> <p>6 don't remember any specific numbers in terms of how</p> <p>7 much could be saved through specialty pharmacy</p> <p>8 contracting.</p> <p>9 Q. Now was that analysis of potential savings</p> <p>10 broken up? In other words, was it we could save X</p> <p>11 number if these drugs were subject to specialty</p> <p>12 pharmacy programs, or was it if we moved all</p> <p>13 specialty drugs to special pharmacy programs, here's</p> <p>14 how much we'd save?</p> <p>15 A. We looked at specific categories and kinds</p> <p>16 of drugs.</p> <p>17 Q. And within specific categories was the</p> <p>18 amount of potential savings calculated?</p> <p>19 A. There were estimates calculated.</p> <p>20 Q. Do you recall whether oncology drugs were</p> <p>21 one category that was assessed?</p> <p>22 A. Yes.</p>	<p style="text-align: right;">129</p> <p>1 also put this in the letter to reiterate the request</p> <p>2 made at a previous deposition for custodian</p> <p>3 information as in Exhibit Coneys 001.</p> <p>4 MR. COCO: I'm sorry?</p> <p>5 MR. MANGI: Did you not hear any of it or</p> <p>6 all of it?</p> <p>7 MR. COCO: You were talking softly. I</p> <p>8 didn't understand.</p> <p>9 MR. MANGI: I'll repeat a request we made</p> <p>10 at an earlier deposition for custodian information</p> <p>11 regarding the document that's been marked as Exhibit</p> <p>12 Coneys 001.</p> <p>13 MR. COCO: And could you put that in a</p> <p>14 follow-up letter?</p> <p>15 MR. MANGI: We would be happy also to put</p> <p>16 that in a follow-up letter.</p> <p>17 MR. COCO: Okay.</p> <p>18 Q. Could you turn, please, to -- if you look</p> <p>19 at Exhibit Coneys 001 you'll see on the bottom left</p> <p>20 there is a number starting with BCBSMA-AWP on the</p> <p>21 left-hand side of the page?</p> <p>22 A. Ah-hah.</p>

Maureen Coneys

April 12, 2006

Boston, MA

34 (Pages 130 to 133)

<p style="text-align: right;">130</p> <p>1 Q. Could you turn to the page numbered 10598, 2 please? Could you please review that page and let 3 me know when you're ready to proceed? 4 A. Okay. 5 Q. At the bottom of that page is a reference 6 to a New York Times article. Do you see that? 7 A. Yes. 8 Q. Do you recall that article? 9 A. I do not. 10 Q. Do you recall any discussion of that 11 article in the NM3 committee? 12 A. I do not. 13 Q. Following that there's discussion that 14 states, "Physicians are able to obtain discounts as 15 high as 86 percent on medications. Plan 16 reimbursement providers for medication is in the 17 range of AWP minus five percent." Is that 18 difference between physicians' drugs acquisition 19 costs and reimbursement an issue that you recall 20 discussed in relation to the implementation of 21 specialty pharmacy programs? 22 A. I do not.</p>	<p style="text-align: right;">132</p> <p>1 created or for what purpose? 2 A. I don't know. 3 Q. If we turn to the page marked 10 which is 4 10601, please, you'll see there is data analysis 5 here dealing with the period of January of '02 until 6 September of '02. Do you see that? 7 A. Yes, I do. 8 Q. Is this the time period for which data 9 analysis was being performed when the NM3 committee 10 was considering whether or not to move to specialty 11 pharmacies? 12 A. I don't remember when NM3 was considering 13 looking at or was looking at specialty pharmacy. 14 Q. Was it generally in the '02 to '04 time 15 period? 16 A. That sounds like it could be a good time 17 period. 18 Q. Is the analysis reflected at page 10 and 19 page 11 the type of analysis that you recall being 20 considered being carried out in contemplation of 21 whether or not the NM3 committee should move to 22 specialty pharmacies?</p>
<p style="text-align: right;">131</p> <p>1 Q. Are you aware of that issue being subject 2 of discussion at BCBS of Massachusetts in any other 3 context? 4 A. I do not. 5 Q. Were you aware of the information 6 memorialized on this page before you just read it 7 now? 8 A. I don't remember seeing it before. 9 Q. Were you aware of the fact before you read 10 this document that there is a difference between the 11 amount which physicians acquire drugs and the 12 amounts that they were reimbursed? 13 A. I was not aware of that. 14 Q. Now looking through the rest of this 15 document is there anything in this document that 16 would give you an understanding as to when or why 17 this was created? 18 MR. COCO: Objection. 19 A. Can you ask me that question again? 20 Q. Sure. Looking through this document is 21 there anything in here that gives you an 22 understanding as to when this would have been</p>	<p style="text-align: right;">133</p> <p>1 A. Yes. 2 Q. And turning to the next page which is page 3 12, are those implementation considerations the same 4 as the issues that the NM3 committee was 5 considering? 6 A. Yes. 7 Q. If we turn to the next page, page 13, does 8 that time line look at all familiar? 9 A. Yes. 10 Q. What does that time frame appear to be? 11 MR. COCO: Objection. 12 A. It appears to be a project time line. 13 Q. Is this the time line -- is this time line 14 familiar to you as a time line pertaining to the NM3 15 committee's contemplation of the move to specialty 16 pharmacies? 17 A. I don't remember the time line, when they 18 were considering it. 19 Q. Does looking at pages 10 through 13 20 refresh your recollection as to whether or not this 21 document was created by the NM3 committee or for the 22 NM3 committee as part of its contemplation to move</p>

Maureen Coneys

April 12, 2006

Boston, MA

35 (Pages 134 to 137)

<p style="text-align: right;">134</p> <p>1 to specialty pharmacies?</p> <p>2 A. On Page 13 it refers to a date on which</p> <p>3 overview of data will be presented to NM3.</p> <p>4 Q. Would that indicate that the answer to my</p> <p>5 question is yes?</p> <p>6 A. Yes.</p> <p>7 MR. COCO: Objection.</p> <p>8 VIDEOGRAPHER: This is the end of tape</p> <p>9 number two. The time is 12:43. We are off the</p> <p>10 record.</p> <p>11 (Brief Recess.)</p> <p>12 Q. Miss Coneys, before the break we were</p> <p>13 talking about the NM3 committee's contemplation of</p> <p>14 specialty pharmacy programs, and you described some</p> <p>15 of the analytical work that was performed.</p> <p>16 What happened after the analytical work</p> <p>17 was complete? What was the next stage in the</p> <p>18 decision-making process?</p> <p>19 MR. COCO: Objection.</p> <p>20 A. I'm not sure I understand what you mean by</p> <p>21 the next.</p> <p>22 Q. Well, the issue first came up and was</p>	<p style="text-align: right;">136</p> <p>1 of?</p> <p>2 A. No.</p> <p>3 Q. How was it anticipated that patient</p> <p>4 disruption may be a concern if specialty pharmacies</p> <p>5 were implemented?</p> <p>6 MR. COCO: Objection.</p> <p>7 A. Many of the drugs that we were talking</p> <p>8 about in terms of potential changes in, you know,</p> <p>9 who we got the drugs from were for conditions that</p> <p>10 were very complicated conditions and very sensitive</p> <p>11 and dependent on the medications that the members</p> <p>12 used and then there was a lot -- the patients become</p> <p>13 very comfortable with, you know, the process and how</p> <p>14 their drugs are supplied to them and what they look</p> <p>15 like and all of those kinds of things, and there was</p> <p>16 concern about the impact it would have on the</p> <p>17 members.</p> <p>18 Q. If a specialty pharmacy program were</p> <p>19 implemented, how would that affect the individual</p> <p>20 member?</p> <p>21 A. They may end up getting their drugs from a</p> <p>22 different vendor than they were getting it from</p>
<p style="text-align: right;">135</p> <p>1 discussed in the NM3 committee before analysis was</p> <p>2 performed, right?</p> <p>3 A. Ah-hah.</p> <p>4 Q. Did the NM3 committee request that the</p> <p>5 analysis be performed?</p> <p>6 A. That's how I remember it, yes.</p> <p>7 Q. After that analysis was performed at the</p> <p>8 committee's request, what happened next?</p> <p>9 A. The company did pursue -- I can't remember</p> <p>10 exactly which drugs, but I believe we pursued</p> <p>11 contracting with specialty pharmacy vendor for</p> <p>12 certain category of specialty drugs.</p> <p>13 Q. Are you aware that the company did not</p> <p>14 implement specialty pharmacy program for drugs that</p> <p>15 were physician-administered?</p> <p>16 A. I am not aware of that.</p> <p>17 Q. Do you know what factors were considered</p> <p>18 in making the decision to apply specialty pharmacy</p> <p>19 programs to some drugs, but not others?</p> <p>20 A. I know that patient disruption was a major</p> <p>21 consideration.</p> <p>22 Q. Any other considerations that you're aware</p>	<p style="text-align: right;">137</p> <p>1 before a specialty pharmacy program would be</p> <p>2 implemented.</p> <p>3 Q. When you use vendor in that context, are</p> <p>4 you referring to a different side of care?</p> <p>5 A. A different supplier of the drug.</p> <p>6 Q. Well, patients would not be acquiring</p> <p>7 specialty drugs themselves, right?</p> <p>8 A. In some -- for some conditions the drugs</p> <p>9 are self-administered.</p> <p>10 Q. Well, I'm trying to understand, however,</p> <p>11 why the program was limited to self-administered</p> <p>12 drugs and not applied to physician-administered</p> <p>13 drugs, and the question is what factors lay behind</p> <p>14 that decision?</p> <p>15 MR. COCO: Objection.</p> <p>16 A. I, first of all, don't recall that we did</p> <p>17 limit it to only patient-administered drugs.</p> <p>18 Q. I'll ask you to assume that to be true</p> <p>19 based on other testimony we received from other BCBS</p> <p>20 witnesses. If that's true, do you have an</p> <p>21 understanding as to some of the issues that were</p> <p>22 considered in determining what the parameters of the</p>

Maureen Coneys

April 12, 2006

Boston, MA

36 (Pages 138 to 141)

<p style="text-align: right;">138</p> <p>1 programs would be?</p> <p>2 MR. COCO: Objection.</p> <p>3 A. No.</p> <p>4 Q. Was patient disruption a concern in</p> <p>5 relation to physician-administered drugs?</p> <p>6 MR. COCO: Objection.</p> <p>7 A. I don't remember discussing physician</p> <p>8 administered drugs.</p> <p>9 Q. Do you recall any discussion of a concern</p> <p>10 that if specialty pharmacy programs were implemented</p> <p>11 across the board to all specialty drugs, then</p> <p>12 physicians may stop administering drugs in their</p> <p>13 offices, patients would have to go to hospitals or</p> <p>14 other sites of care?</p> <p>15 A. I do remember some discussion around that.</p> <p>16 Q. Was that a concern to BCBS of</p> <p>17 Massachusetts?</p> <p>18 A. Yes.</p> <p>19 MR. COCO: Objection.</p> <p>20 Q. Was that a concern for the same reasons</p> <p>21 you mentioned earlier that patients become</p> <p>22 comfortable with getting their care in a particular</p>	<p style="text-align: right;">140</p> <p>1 Coneys 001 to page six of that document, please?</p> <p>2 There's a section there entitled, "Special Handling,</p> <p>3 Dosing and Patient Support Requirements." If you</p> <p>4 take a moment to review that and let me know when</p> <p>5 you're ready to proceed, please.</p> <p>6 Do you recall any discussion of these</p> <p>7 issues relating to specialty drugs in the NM3</p> <p>8 committee?</p> <p>9 A. Yes. These were some of the issues that</p> <p>10 were discussed in terms of patient disruption.</p> <p>11 Q. How were these issues considered relevant</p> <p>12 to patient disruption?</p> <p>13 MR. COCO: Objection.</p> <p>14 A. Because as it says in here, the specialty</p> <p>15 drug companies provide clinical support and, as I</p> <p>16 understand it, the patients become accustomed to</p> <p>17 dealing with certain people and turning to certain</p> <p>18 people with questions about their drugs or about the</p> <p>19 administration or dosage and so forth of the drugs.</p> <p>20 Q. When you were the executive director of</p> <p>21 the Braintree site, do you recall your physicians or</p> <p>22 your site having to deal with some of these special</p>
<p style="text-align: right;">139</p> <p>1 setting?</p> <p>2 A. Yes.</p> <p>3 Q. Since the original determination as to the</p> <p>4 scope of the specialty pharmacy program was made by</p> <p>5 the NM3 committee, has the issue of specialty</p> <p>6 pharmacies been revisited by the committee?</p> <p>7 A. It has not been revisited by NM3. It's</p> <p>8 being handled elsewhere in the company.</p> <p>9 Q. What group or committee is currently</p> <p>10 tasked with specialty pharmacy issues?</p> <p>11 A. I believe it's within the pharmacy</p> <p>12 management area.</p> <p>13 Q. Do you know who's in charge of that area?</p> <p>14 A. It's under Deb Devaux.</p> <p>15 Q. Do you know whether anyone in Miss</p> <p>16 Devaux's department, in particular, is responsible</p> <p>17 for considering issues relating to specialty</p> <p>18 pharmacies?</p> <p>19 A. It used to be John Killion. I don't know</p> <p>20 that he, for sure, whether he is still responsible.</p> <p>21 The last time I dealt with specialty drugs he was.</p> <p>22 Q. Could I ask you to turn back to Exhibit</p>	<p style="text-align: right;">141</p> <p>1 handling requirements around specialty drugs?</p> <p>2 A. I do not.</p> <p>3 Q. Do you know whether there were any</p> <p>4 particular resources or amounts spent on handling</p> <p>5 specialty drugs by the Braintree site?</p> <p>6 A. I don't know.</p> <p>7 Q. But as part of your NM3 committee</p> <p>8 consideration, you did have an understanding of this</p> <p>9 document that there are particular handling</p> <p>10 requirements unique to specialty drugs?</p> <p>11 MR. COCO: Objection.</p> <p>12 A. At least certain specialty drugs.</p> <p>13 Q. And those particular handling</p> <p>14 requirements, if left with a doctor, would impose a</p> <p>15 higher cost from the doctor, correct?</p> <p>16 A. I don't know that.</p> <p>17 Q. Well, there's a higher handling cost and</p> <p>18 someone has to pay, is that a fair statement?</p> <p>19 MR. COCO: Objection.</p> <p>20 A. Again, I don't -- I don't know what you're</p> <p>21 asking me.</p> <p>22 Q. Okay. Well, let me try and break it down</p>

Maureen Coneys

April 12, 2006

Boston, MA

37 (Pages 142 to 145)

<p style="text-align: right;">142</p> <p>1 then. You understood as part of your consideration</p> <p>2 in the NM3 committee that certain specialty drugs</p> <p>3 have special handling requirements, correct?</p> <p>4 A. Right.</p> <p>5 Q. Such as the refrigeration and things like</p> <p>6 that, right?</p> <p>7 A. Right.</p> <p>8 Q. And you understood also that there was a</p> <p>9 cost associated with that special handling, correct?</p> <p>10 MR. COCO: Objection.</p> <p>11 A. I don't -- I don't know that there's a</p> <p>12 cost associated with it.</p> <p>13 Q. Well, for refrigeration you would need a</p> <p>14 refrigerator and you would have electrical expenses</p> <p>15 associated with running it, right?</p> <p>16 MR. COCO: Objection.</p> <p>17 A. I don't know if those are additional</p> <p>18 expenses beyond what a physician or a patient would</p> <p>19 have in their home or office.</p> <p>20 Q. Are you familiar with the provider of</p> <p>21 financial strategies work?</p> <p>22 A. No, I'm not.</p>	<p style="text-align: right;">144</p> <p>1 Q. Were you familiar with the settlement that</p> <p>2 was reached regarding those allegations?</p> <p>3 A. No.</p> <p>4 Q. Are you aware that one aspect of the</p> <p>5 settlement involved additional monitoring?</p> <p>6 A. No.</p> <p>7 Q. Are you familiar at all with any</p> <p>8 monitoring that was implemented as a consequence of</p> <p>9 that settlement?</p> <p>10 A. No.</p> <p>11 Q. Did you do anything to prepare for your</p> <p>12 deposition today?</p> <p>13 A. No.</p> <p>14 Q. Did you meet with any of your lawyers in</p> <p>15 preparation for this deposition?</p> <p>16 A. I did meet with my attorneys.</p> <p>17 Q. Did you meet with both Mr. Coco and Mr.</p> <p>18 Skwara?</p> <p>19 A. Yes.</p> <p>20 Q. When did you meet with them?</p> <p>21 A. Monday.</p> <p>22 Q. How long did you meet with them for?</p>
<p style="text-align: right;">143</p> <p>1 Q. Are you aware of the fact that in recent</p> <p>2 years BCBS of Massachusetts considered whether or</p> <p>3 not it should change its methodology used for</p> <p>4 reimbursing physicians for drugs that they</p> <p>5 administered in their offices?</p> <p>6 A. No, I'm not aware of that.</p> <p>7 Q. Are you aware that a move was contemplated</p> <p>8 from AWP-based reimbursement to ASP-based</p> <p>9 reimbursement in that setting?</p> <p>10 A. No, I'm not.</p> <p>11 Q. Are you aware that in 1994 BCBS of</p> <p>12 Massachusetts settled with the government</p> <p>13 allegations that it had inflated claims in relation</p> <p>14 to Medicare?</p> <p>15 MR. COCO: Objection.</p> <p>16 A. I'm not aware of that.</p> <p>17 Q. Are you aware of any litigation in 1994 or</p> <p>18 thereabouts in relation to BCBS of Massachusetts</p> <p>19 processing of Medicare claims?</p> <p>20 A. Again, I was aware there was litigation.</p> <p>21 I was not familiar with what the terms, you know, of</p> <p>22 the litigation were, what it was about.</p>	<p style="text-align: right;">145</p> <p>1 A. One hour.</p> <p>2 Q. Did you meet with anyone else in relation</p> <p>3 to this litigation?</p> <p>4 A. No.</p> <p>5 Q. Did you review any deposition transcripts</p> <p>6 in preparation for the deposition?</p> <p>7 A. No.</p> <p>8 Q. Did you review any documents in</p> <p>9 preparation for the deposition?</p> <p>10 A. No.</p> <p>11 Q. In the context of this litigation were</p> <p>12 you, at any time, asked to search your files for</p> <p>13 documents?</p> <p>14 A. No.</p> <p>15 Q. Have you, in fact, searched your files for</p> <p>16 documents relevant to this litigation?</p> <p>17 MR. MANGI: For the record we'd ask a</p> <p>18 search of Miss Coneys' files be carried out. We</p> <p>19 were under the impression that a search had been</p> <p>20 carried out, and no responsive documents have been</p> <p>21 found.</p> <p>22 We reserve the right to call back the</p>

Maureen Coneys

April 12, 2006

Boston, MA

38 (Pages 146 to 149)

<p style="text-align: right;">146</p> <p>1 witness if documents are subsequently discovered.</p> <p>2 Q. I'd like to ask you about the BC65 program</p> <p>3 we touched on earlier. BC65 you were responsible</p> <p>4 for deals with the government in relation to that</p> <p>5 program from '97 to 2001 when you were the VP for</p> <p>6 government programs, correct?</p> <p>7 A. Correct.</p> <p>8 Q. As the VP for government programs did you</p> <p>9 have any responsibilities in relation to that</p> <p>10 program other than dealing with the government in</p> <p>11 relation to that capitated rate?</p> <p>12 A. I'm sorry. Could you explain what you</p> <p>13 mean?</p> <p>14 Q. Sure. One aspect of your work was dealing</p> <p>15 with the government in relation to issues stemming</p> <p>16 from the BC65 program, correct?</p> <p>17 A. Correct.</p> <p>18 Q. That included the rate, the capitated rate</p> <p>19 that the government would pay to BCBS of</p> <p>20 Massachusetts, did it?</p> <p>21 A. It included the supplemental premium that</p> <p>22 we were charged members.</p>	<p style="text-align: right;">148</p> <p>1 A. I don't remember the date.</p> <p>2 Q. Do you know the year or the time period?</p> <p>3 A. I don't remember.</p> <p>4 Q. Was it prior to 2000?</p> <p>5 A. Yes.</p> <p>6 Q. Was it prior to your coming into the role</p> <p>7 as VP of government --</p> <p>8 A. Yes.</p> <p>9 Q. Is that still in existence today?</p> <p>10 A. Yes.</p> <p>11 Q. Do you know what methodology BCBS of</p> <p>12 Massachusetts uses to reimburse physicians who treat</p> <p>13 patients under the BC65 product?</p> <p>14 A. It's fee for service.</p> <p>15 Q. Do you know how the fees are calculated on</p> <p>16 those fee schedules?</p> <p>17 A. I do not.</p> <p>18 Q. Are you aware that in recent years BCBS of</p> <p>19 Massachusetts contemplated changing the methodology</p> <p>20 that was used to calculate the amount to reimburse</p> <p>21 to physicians treating patients covered by the BC65</p> <p>22 product?</p>
<p style="text-align: right;">147</p> <p>1 Q. Did it also include determination of the</p> <p>2 rate, the capitated rate that CMS would pay to BCBS</p> <p>3 of Massachusetts?</p> <p>4 A. I didn't discuss that directly.</p> <p>5 Q. Did you have a role in relation to the</p> <p>6 operation of the BC65 program, itself, in terms of</p> <p>7 contracting with physicians, product design, things</p> <p>8 of that kind?</p> <p>9 A. I had. I was involved in product design,</p> <p>10 network design, but not contracting with physicians.</p> <p>11 Q. After 2001 when you became the VP for</p> <p>12 health care quality and cost, did you retain any</p> <p>13 role in relation to the BC65 program?</p> <p>14 A. I did.</p> <p>15 Q. I'm sorry?</p> <p>16 A. I did retain.</p> <p>17 Q. What were the responsibilities that you</p> <p>18 retained in relation to the BC65 program?</p> <p>19 A. I retained the same responsibilities I had</p> <p>20 prior to 2000.</p> <p>21 Q. Do you know when the BC65 product was</p> <p>22 launched?</p>	<p style="text-align: right;">149</p> <p>1 A. No.</p> <p>2 MR. COCO: Objection.</p> <p>3 Q. Are you familiar with the term, ASP?</p> <p>4 A. No.</p> <p>5 Q. Are you aware of the fact that Medicare</p> <p>6 has recently changed the methodology whereby it</p> <p>7 calculates the amount reimbursed to physicians for</p> <p>8 drugs administered in their offices?</p> <p>9 A. No.</p> <p>10 Q. Do you know whether or not the</p> <p>11 reimbursement methodology utilized for the BC65</p> <p>12 product has changed over time or has remained the</p> <p>13 same?</p> <p>14 A. I don't know.</p> <p>15 Q. Do you have any responsibility in relation</p> <p>16 to communications between BCBS of Massachusetts and</p> <p>17 physicians in specific to the BC65 product?</p> <p>18 A. No.</p> <p>19 Q. Do you review such communications before</p> <p>20 they go out?</p> <p>21 A. No.</p> <p>22 Q. We spoke about drugs. Do you know whether</p>

Maureen Coneys

April 12, 2006

Boston, MA

39 (Pages 150 to 153)

<p style="text-align: right;">150</p> <p>1 the amount reimbursed to physicians for services 2 rendered in treating patients covered by the BC65 3 product has changed over time? 4 A. I don't know. 5 MR. MANGI: Let's mark this as Exhibit 6 Coneys 002. 7 (Boston Globe Article dated 6/29/00 8 marked Exhibit Coneys 002.) 9 Q. Now this is an article from the Boston 10 Globe from June of 2000 that quotes you. Are you 11 familiar with this article? 12 A. I don't remember. 13 Q. Take a moment and familiarize yourself 14 with it, and let me know when you're ready to 15 proceed, please. 16 A. Okay. 17 Q. Does reading this article refresh your 18 recollection as to whether or not you've seen it 19 before? 20 A. I've seen it before. 21 Q. Now I believe this discusses an issue you 22 referenced earlier regarding premiums and</p>	<p style="text-align: right;">152</p> <p>1 expensive, sometimes more expensive than other HMO 2 products that were on the market. 3 Q. The BC65 program offered members the 4 various options in terms of the level of coverage 5 they would receive, correct? 6 MR. COCO: Objection. 7 A. I believe initially when the product was 8 launched there were two different products; one that 9 had drugs and one that did not. Eventually during 10 the time I was running the product we were only 11 offering one product option. 12 Q. Was that the option with drugs or without 13 drugs? 14 A. With drugs. 15 Q. Looking at the first page of this article, 16 the second paragraph from the bottom, refers to Miss 17 Patty Blake, Secure Horizons, who said that the 18 rates Medicare pays Tufts to care for seniors is so 19 low that the HMO has little choice but to establish 20 across-the-board premiums. Was a similar dynamic in 21 play leading to the premiums charged by BCBS of 22 Massachusetts?</p>
<p style="text-align: right;">151</p> <p>1 supplemental premiums, is that correct? 2 A. Right, right. 3 Q. When the BC65 product first launched and 4 when you were first familiar with it, were premiums 5 being charged to members? 6 A. You know, I don't remember when the 7 product was first launched, whether there was a 8 supplemental premium or not. As far as I can 9 remember for the period of time that I was 10 responsible for it there was a premium. 11 Q. Is that a -- were those monthly premiums 12 paid by members? 13 A. Yes. 14 Q. From the patient's perspective are those 15 premiums different from what they would have paid if 16 they enrolled in Medicare directly? 17 A. To enroll -- to enroll in an HMO plan they 18 have to be enrolled in Medicare. If they were to 19 buy supplemental coverage, then what we were 20 charging was less than what they would have to pay 21 if they bought supplemental coverage for a metigap 22 (phonetics) product, but in line sometimes less</p>	<p style="text-align: right;">153</p> <p>1 A. Yes. 2 MR. COCO: Objection. 3 Q. Was a concern over the adequacy of the 4 capitated rate paid directly by Medicare that played 5 a role in the setting in increases to monthly 6 premiums charged to members, right? 7 A. Correct. 8 Q. Second page of this document there's a 9 paragraph in the middle of the page starting with, 10 "For example, Blue Cross Blue Shield." Do you see 11 that? 12 A. Ah-hah. 13 Q. It says the HMO pays \$500 a year per 14 senior for drugs and members cover the rest. What 15 is meant by that? 16 A. It means that the plan, Bluecare 65, would 17 pay for \$500 worth of drugs, prescription drugs, and 18 anything over that the member would be responsible 19 for paying on their own. 20 Q. Was there always a -- well, how long was 21 this \$500 cap on drugs spending in effect? 22 A. I don't remember specifically how long we</p>

Maureen Coneys

April 12, 2006

Boston, MA

40 (Pages 154 to 157)

<p style="text-align: right;">154</p> <p>1 had a \$500 drug benefit.</p> <p>2 Q. How long has there been a cap?</p> <p>3 A. For several years, but I don't remember</p> <p>4 exactly when it began being capped.</p> <p>5 Q. Has the amount changed over time?</p> <p>6 A. It has.</p> <p>7 Q. What's the current?</p> <p>8 A. I believe it's \$600.</p> <p>9 Q. Does that amount include both self-</p> <p>10 administered drugs as well as physician-administered</p> <p>11 drugs?</p> <p>12 A. No. It includes only prescription drugs.</p> <p>13 Q. By prescription drugs you're referring to</p> <p>14 self-administered drugs?</p> <p>15 A. Correct.</p> <p>16 Q. Physician-administered drugs are covered</p> <p>17 under BC65 and are not subject to this cap?</p> <p>18 A. That's right.</p> <p>19 Q. Turning to the third and last page of that</p> <p>20 document here's a section where it refers to you and</p> <p>21 quotes you. You indicated that Blue Cross Blue</p> <p>22 Shield wanted to expand BC65 to new parts of western</p>	<p style="text-align: right;">156</p> <p>1 not sure what I meant by it's more of a financial</p> <p>2 risk for them.</p> <p>3 Q. Okay. Well, let's stick with the first</p> <p>4 part of sentence for a minute. There's limited</p> <p>5 number of providers. Fair enough. Then you refer</p> <p>6 to a reluctance to contract with Medicare plans. Do</p> <p>7 you know why providers were reluctant to contract</p> <p>8 with Medicare plans?</p> <p>9 A. There were additional rules that were</p> <p>10 required in terms of again referrals and patient</p> <p>11 management that are typical to an HMO that don't</p> <p>12 exist in a traditional Medicare program, so there</p> <p>13 was more administrative.</p> <p>14 Q. Anything else?</p> <p>15 A. Different plans have different</p> <p>16 reimbursement methods. I believe that they pay to</p> <p>17 the providers and some of them did do capitations I</p> <p>18 think particularly back in this period of time, and</p> <p>19 physicians didn't want to be at risk for, you know,</p> <p>20 the cost and use of Medicare beneficiaries.</p> <p>21 Q. Were you expressing here a view that</p> <p>22 providers -- that contracting with Medicare plans</p>
<p style="text-align: right;">155</p> <p>1 Massachusetts if you could convince providers to</p> <p>2 sign onto the program. Now this article is from</p> <p>3 June of 2000. Since that time has the BC65 program</p> <p>4 been expanded?</p> <p>5 MR. COCO: Objection.</p> <p>6 A. I actually don't know. I can't remember</p> <p>7 whether we ever did expand in that area or not.</p> <p>8 Q. You say in this quote here, "There are a</p> <p>9 limited number of providers and a reluctance to</p> <p>10 contract with Medicare plans. It's more of a</p> <p>11 financial risk for them." What did you mean by</p> <p>12 that?</p> <p>13 A. The providers -- I'm trying to think back</p> <p>14 to what I meant. I believe what I was referring to</p> <p>15 here was just not physician providers, but hospital</p> <p>16 providers as well that we -- that for providers,</p> <p>17 hospital providers who are in the network, our</p> <p>18 reimbursement motto was per diem motto and Medicare</p> <p>19 or DRG -- I can't really tell you exactly what I</p> <p>20 meant.</p> <p>21 I don't know what I was responding to or</p> <p>22 what question she asked me when I said this, so I'm</p>	<p style="text-align: right;">157</p> <p>1 was financially less attractive to providers than</p> <p>2 contracting with private plans?</p> <p>3 MR. COCO: Objection.</p> <p>4 A. It wouldn't be contracting with private</p> <p>5 plans. It would just be being part of the Medicare</p> <p>6 program.</p> <p>7 Q. So the comparison you're making here is</p> <p>8 between a provider who will contract with a managed</p> <p>9 Medicare product with a plan like BCBS Massachusetts</p> <p>10 versus a provider who will deal directly with</p> <p>11 Medicare?</p> <p>12 A. Right.</p> <p>13 Q. And you indicated that dealing with a</p> <p>14 managed Medicare product provider like BCBS of</p> <p>15 Massachusetts would be more of a financial risk for</p> <p>16 a physician than dealing directly with Medicare?</p> <p>17 MR. COCO: Objection.</p> <p>18 A. Again, I don't remember what I was</p> <p>19 referring to when I talked about financial risk.</p> <p>20 Q. Let me just clarify the question. I</p> <p>21 understand you don't know specifically what you were</p> <p>22 referring to when you said financial risk. I'm just</p>

Maureen Coneys

April 12, 2006

Boston, MA

41 (Pages 158 to 161)

<p style="text-align: right;">158</p> <p>1 trying to understand the comparison you were making.</p> <p>2 In other words, regardless of what you</p> <p>3 meant were you saying there is more of a financial</p> <p>4 risk for providers when dealing with managed</p> <p>5 Medicare product through an entity such as Blue</p> <p>6 Cross Blue Shield versus contracting directly with</p> <p>7 Medicare, or were you drawing some other comparison?</p> <p>8 MR. COCO: Objection.</p> <p>9 A. I was saying that it's more complex for</p> <p>10 them to deal with an HMO in terms of the demands</p> <p>11 around patient management and so forth that go with</p> <p>12 being part of an HMO.</p> <p>13 Q. And you don't recall what you meant or</p> <p>14 don't understand what you meant when you referred to</p> <p>15 financial risk in this context?</p> <p>16 A. I don't.</p> <p>17 MR. COCO: Objection.</p> <p>18 MR. MANGI: Why don't we take a break?</p> <p>19 (Brief Recess.)</p> <p>20 Q. Miss Coneys, we spoke about the VP for</p> <p>21 healthcare quality part of your job. I'd like to</p> <p>22 ask you about the VP for cost as part of your title.</p>	<p style="text-align: right;">160</p> <p>1 Q. Turning back for a moment to the BC65</p> <p>2 program, we mentioned in this article that there was</p> <p>3 a \$500 cap at one point on drug --</p> <p>4 A. Right.</p> <p>5 Q. -- coverage. Did I understand correctly</p> <p>6 that the only BC65 product offered now is a product</p> <p>7 that includes drug coverage?</p> <p>8 A. I believe that's still true.</p> <p>9 Q. In other words individuals don't have an</p> <p>10 option to enroll in a BC65 program that would</p> <p>11 exclude drugs?</p> <p>12 MR. COCO: Objection.</p> <p>13 A. I don't believe so.</p> <p>14 Q. In addition to the supplemental payments</p> <p>15 that they're making, do the BC65 members also have</p> <p>16 coinsurance or copayment obligations?</p> <p>17 A. Yes.</p> <p>18 Q. How are those amounts calculated?</p> <p>19 A. I'm sorry?</p> <p>20 Q. How are those amounts calculated?</p> <p>21 A. They're determined as part of the benefit</p> <p>22 design process.</p>
<p style="text-align: right;">159</p> <p>1 What does that aspect of your role involve?</p> <p>2 A. It relates to utilization review and care</p> <p>3 management programs.</p> <p>4 Q. What are care management programs?</p> <p>5 A. Disease management, case management,</p> <p>6 coaching programs.</p> <p>7 Q. Does BCBS perform any analysis of the</p> <p>8 amount it's spending in terms of drug reimbursement?</p> <p>9 MR. COCO: Objection.</p> <p>10 A. We look at prescription drug utilization</p> <p>11 and cost.</p> <p>12 Q. Does that include both self-administered</p> <p>13 drugs and physician-administered drugs?</p> <p>14 A. No, it doesn't include physician-</p> <p>15 administered drugs.</p> <p>16 Q. Those are specifically excluded from the</p> <p>17 analysis?</p> <p>18 A. I don't believe they are prescription</p> <p>19 drugs.</p> <p>20 Q. So the only analysis that you're familiar</p> <p>21 with excludes physician-administered drugs?</p> <p>22 A. Yes.</p>	<p style="text-align: right;">161</p> <p>1 Q. Are they flat co-pays or percentage co-</p> <p>2 insurance?</p> <p>3 A. They're co-pays.</p> <p>4 Q. \$5 sums?</p> <p>5 A. Yes.</p> <p>6 Q. Do you know whether Blue Cross Blue Shield</p> <p>7 of Massachusetts contracts with physicians --</p> <p>8 withdraw that -- contracts with drug manufacturers?</p> <p>9 A. No.</p> <p>10 Q. Are you familiar with the P&T committee of</p> <p>11 pharmacy and therapeutics committee?</p> <p>12 A. I know there is one.</p> <p>13 Q. Are you a part of that committee?</p> <p>14 A. No.</p> <p>15 Q. You ever been a part of that committee?</p> <p>16 A. No.</p> <p>17 Q. Do you have any knowledge or understanding</p> <p>18 as to the amount at which entities in the market, be</p> <p>19 they physicians, hospitals, anyone else, acquired</p> <p>20 drugs?</p> <p>21 A. No.</p> <p>22 Q. Do you have an understanding as to whether</p>

Maureen Coneys

April 12, 2006

Boston, MA

42 (Pages 162 to 164)

<p style="text-align: right;">162</p> <p>1 or not or to what extent discounts and rebates are 2 available on drugs to purchasers in the market? 3 A. I do not. 4 Q. Are you familiar or have you heard the 5 term W-A-C, WAC, or wholesale acquisition cost? 6 A. No. 7 MR. MANGI: Okay, I have nothing further. 8 MR. COCO: Did you have anything? 9 MR. MIZELL: No. 10 MR. COCO: Okay. Just for the record 11 during the break we did review the fact that even 12 though Miss Coneys does not remember it, that a 13 request was made to her to search for documents and 14 a response was received that she did not have any, 15 but she has no recollection of that. 16 We believe it was about the time you 17 served the notice for her deposition, so that is the 18 basis for, you know, my representations that a 19 search had been done and she was not aware, but we 20 will go back and just double-check that to make sure 21 that that was done. 22 MR. MANGI: I appreciate the clarification</p>	<p style="text-align: right;">164</p> <p>1 Commonwealth of Massachusetts 2 South Middlesex, ss. 3 I, Teresa E. Costello, Notary Public in and for the 4 Commonwealth of Massachusetts, do hereby certify that there 5 came before me on the 12th day of April, 2006, MAUREEN CONEYS, 6 who was duly sworn by me; that the ensuing examination upon oath 7 of the said deponent was reported stenographically by me and 8 transcribed into typewriting under my direction and control; 9 and that the within transcript is a true record of the questions 10 asked and answers given at said deposition. 11 I FURTHER CERTIFY that I am neither attorney nor counsel 12 for, nor related to or employed by any of the parties to the action 13 in which this deposition is taken; and, further, that I am not a 14 relative or employee of any attorney or financially interested in 15 the outcome of the action. 16 IN WITNESS WHEREOF I have hereunto set my hand and affixed 17 my seal of office this 14th day of April, 2006, at Framingham. 18 19 Teresa E. Costello, RPR, 20 CSR, #1452S98 21 Notary Public, Commonwealth of Massachusetts 22 My Commission Expires: 5/29/09</p>
<p style="text-align: right;">163</p> <p>1 and we'd request that either the search be re- 2 performed with reference to the entirety of the 3 document request or that documentation reflecting 4 that the search was previously performed, one or the 5 other, in light of the testimony. Okay. Nothing 6 further. 7 (Whereupon the deposition concluded 8 at 1:44 p.m.) 9 10 11 12 13 <u>MAUREEN CONEYS</u> 14 15 Subscribed and sworn to and before me 16 this _____ day of _____, 20____. 17 18 19 20 <u>Notary Public</u> 21 22</p>	

Maureen Coneys

April 12, 2006

Boston, MA

1

A	124:19	22:1 57:19	99:3,7,12	annualized
aamangi@pb...	activity 49:17	62:15 96:2	102:5 108:5	128:8
2:21	49:19 114:9,10	140:19	109:22 110:7	answer 7:22 8:5
able 130:14	actual 21:6	administrative	116:22 126:19	16:4,5 17:12
accept 81:7	65:18 68:11	45:17 64:11	127:18 131:11	134:4
accepting 78:13	90:18	65:17,18 89:11	148:20 149:7	answers 164:10
access 92:15	actuals 69:4,13	156:13	150:1 154:5,9	anticipated 70:3
108:13	73:7,10,15	admission 15:11	159:8 161:18	71:19 73:5,6
accounting	actuarial 125:2	17:6 20:1,3,5,7	amounts 14:3	136:3
51:20,22	125:8 127:2	admissions	27:15 29:11,19	anybody 118:1
accounts 51:20	addition 107:19	15:17 21:2,7	31:12 70:20	appear 133:10
51:21	160:14	admit 19:21	81:22 82:5	APPEARAN...
accredit 113:9	additional 92:15	admitted 15:10	91:12 94:10	2:1 3:1
accreditation	93:5 94:10	admitting 20:2	100:2,4,22	appears 133:12
113:8,10,14,22	104:18 116:2	adopted 77:15	108:22 109:6,9	applied 31:16
accurate 27:12	142:17 144:5	86:2	111:12,18	31:17 114:5
111:21	156:9	advance 62:16	112:4 126:7,17	117:17 137:12
accustomed	address 12:9,19	advanced 72:7	131:12 141:4	apply 135:18
83:5 140:16	24:10 93:22	affect 70:11	160:18,20	appreciate
achieve 116:3	addressed 13:7	73:7,10 136:19	analyses 17:15	162:22
acquire 57:19	13:10	affixed 164:16	analysis 18:18	approach 94:6
62:2 131:11	addressing	aggregate 126:5	21:20 52:2,5,7	approached
acquired 57:13	12:14 90:16	ago 123:3	52:16,21 63:11	94:5
57:16 58:13	Adeel 2:18 5:12	agreed 116:3	66:9 123:19	appropriate
59:1 93:10	6:9	agreeing 81:7	124:15,22	11:22 12:3,11
161:19	adequacy 153:3	Ah-hah 98:13	125:1,5,13,15	19:13,15 20:18
acquiring 50:16	administer	129:22 135:3	126:17,22	23:2
51:1 52:8 78:2	42:18 57:14	153:12	127:4,9 128:2	appropriately
109:12 137:6	62:3 82:10	ain't 120:1	128:4,12,16	26:3
acquisition	126:8	Alan 96:21	132:4,9,18,19	appropriaten...
50:19 52:16	administered	allegation 7:14	135:1,5,7	15:11,14,17
58:21 59:9	13:4,21 26:22	allegations	159:7,17,20	17:5
121:2 130:18	42:7 62:19	143:13 144:2	analytical 63:12	approval 21:14
162:5	66:9 81:18	allow 108:13	134:15,16	approve 20:7
acronym 120:10	87:10 91:13	alternatives	analyzed 18:14	approximate
across-the-bo...	108:18 109:4	94:7	125:9,22	44:9 60:3,7
152:20	118:9 138:8	Americas 2:19	analyzing 124:3	approximately
action 164:12,15	143:5 149:8	amount 29:17	126:3	43:9,18 46:21
ACTIONS 1:10	154:10 159:15	31:15 63:4	ancillary 125:2	101:18
activities 45:19	administering	70:12 71:1,12	annual 54:6,20	approximating
46:5 51:22	110:1 138:12	71:14 89:19	55:6,9,10 56:6	60:12
95:14 113:8	administration	90:16,22 91:13	68:15	April 1:21 5:5

Maureen Coneys

April 12, 2006

Boston, MA

2

164:5,17	52:6 56:1 71:8	Avenue 2:19	basis 38:13	108:12 113:22
area 9:21 22:10	89:11 94:22	avenues 23:17	68:16,16 70:17	117:1,5,21
22:10,11 23:8	105:4	24:4 38:11	83:13 88:17	118:6,11 123:1
23:9,10,10	ASP-based	average 1:6 5:9	102:21 117:12	131:2 137:19
25:20,22 36:17	143:8	119:10 120:9	124:12 126:5	138:16 143:2
53:10,20 87:2	assessed 68:15	awaiting 62:15	126:14 128:8	143:11,18
92:15 94:7	115:1 127:21	aware 17:15,20	162:18	146:19 147:2
103:18,19	assessing 73:8	18:9 110:20	Bay 7:5,7,15	148:11,18
113:7 114:18	assessment	112:11,14	11:3,5,8,13	149:16 152:21
125:3,7 127:2	16:10 114:10	117:14,18	14:8,17,18	157:9,14 159:7
139:12,13	116:8	118:11,15	15:2,7,9 16:9	BCBSMA-A...
155:7	assign 26:12	131:1,5,9,13	17:7,10,16	129:20
areas 30:6,9,14	assigned 29:2	135:13,16,22	18:20 19:4,10	BC65 101:20
30:19 31:2,4,8	assistants 46:16	143:1,6,7,11	19:12,14 20:1	102:13 103:16
33:6 37:4	assisted 46:4	143:16,17,20	20:2,6,7,10	104:3 146:2,3
49:14 64:11	associated 142:9	144:4 148:18	21:8 22:5,22	146:16 147:6
93:21 95:20	142:12,15	149:5 162:19	24:19 25:9,12	147:13,18,21
arrangement	associates 66:21	AWP 118:13	25:16 26:18	148:13,21
105:5,8	67:3,15,19	119:5,11,12,20	27:20 28:2,4	149:11,17
arrangements	77:17	120:1 130:17	29:11,16 32:17	150:2 151:3
54:15	assume 137:18	AWP-based	34:15 119:6,9	152:3 154:17
arrive 82:18	assumed 65:16	143:8	119:14,17	154:22 155:3
artery 121:15	65:17,19,22	a.m 1:21	120:7	160:1,6,10,15
article 4:11	assumption		BCBS 14:14	began 32:17
130:6,8,11	70:22	B	15:4 32:19	78:12 154:4
150:7,9,11,17	Assurance	B 4:7	33:2,14 34:5	behalf 1:14 5:14
152:15 155:2	113:15	baby 32:1	34:14,22 39:22	124:13
160:2	attention 92:19	back 6:17 8:22	53:7,13,17,20	Behavioral
aside 21:6,11	attorney 64:9	49:22 62:12	54:16 56:22	15:22
asked 28:13	164:11,14	104:3 139:22	57:5,8 59:13	believe 22:11
74:9 145:12	attorneys	145:22 155:13	59:17 64:1,4	29:20 35:3,22
155:22 164:10	144:16	156:18 160:1	67:5,11 72:18	44:5 47:4 49:7
asking 6:9	attractive 157:1	162:20	74:3 76:7	56:17 62:21
104:16 141:21	attributed 72:1	background 9:1	77:21 78:6	77:1 79:16
ASP 149:3	72:22 73:2,3	Bacon 3:3 5:16	81:6 82:4,9	94:16 98:6
aspect 16:20	73:17	bandages 96:9	83:14 85:12,14	100:7,21
22:22 72:5	audibly 8:1 16:4	based 19:10	95:8,12 99:4	106:17 107:7
95:17 113:21	authorization	63:7,8 65:16	99:15,19,22	115:18 123:3
115:16 144:4	21:1	68:11 70:15	100:2,8 101:5	124:18 127:1
146:14 159:1	available 57:15	72:2,9 99:9	102:4,7 104:6	135:10 139:11
aspects 15:15	57:20 162:2	115:12 118:14	105:6,11,17	150:21 152:7
16:7 45:16	Aventis 3:8 5:16	137:19	106:16 108:5	154:8 155:14
		basically 12:6		

Maureen Coneys

April 12, 2006

Boston, MA

3

156:16 159:18 160:8,13 162:16 Belknap 2:17 5:13 benchmarking 124:19 125:10 125:15,21 126:11 beneficiaries 156:20 benefit 86:15 92:3 103:1 154:1 160:21 benefits 24:6 33:4,7,10,19 beyond 63:18 97:8 120:10 142:18 big 44:11,11,12 bigger 61:11 bill 49:11 110:6 birth 28:9 bit 8:22 13:1 90:13 104:4 Blake 152:17 Blue 2:7,7,9,9 2:14,14 5:17 5:18,20,20 7:2 7:16 8:11,12 10:11,11,13,13 10:19,20 11:5 11:5,16,16 13:12,12,18,19 14:7,7 32:4,4,8 33:16,16 34:1 34:1,4,4,17 36:8,8 38:1,1,5 38:5,22,22 44:18,19 49:17 49:21 59:15 61:7,9 64:10	64:10 67:21,21 73:22 74:11,14 74:16,16,20 75:5,13,16,18 75:20 76:2,17 77:10,10,18 78:9,15 80:14 81:3,8,11 82:22 83:3,3,9 83:13,14,17 84:15,18,22 85:3,7,16,18 85:19 86:4,10 86:22 87:9 89:21 91:21 92:21 93:5 94:15,18,19 95:1,2,4 99:1 99:17 100:6 103:11 104:10 107:2,12,16 114:5,5 118:2 118:2 121:16 153:10,10 154:21,21 158:5,6 161:6 161:6 Bluecare 98:18 103:2,17,19 104:1 153:16 board 29:13 138:11 body 27:17 books 26:11 Boston 1:20 2:5 2:13 4:11 5:4,7 150:7,9 bottom 129:19 130:5 152:16 bought 80:6 151:21 Boulevard 3:5	Boylston 1:20 2:4 Braintree 36:10 36:15 40:13 43:7,12,21,22 44:10,14 45:9 46:21 47:18 51:14 52:17 53:7 54:1,7,16 54:22 55:9,12 55:15,19 56:1 56:8,11,14 57:9 58:2,5 61:14 62:21 63:1,4,11,14 65:9,13 66:3 66:20,22 67:3 67:15,19 68:13 70:3 72:22 73:1,2,4,6 74:3 76:11 77:16,17 109:16 110:17 111:2 112:2 140:21 141:5 break 8:9 53:5 55:5 68:9 84:13 106:13 134:12 141:22 158:18 162:11 Brief 53:4 106:14 134:11 158:19 briefly 68:8 bringing 36:3 broad 74:13 84:1,9 broken 66:14 127:10 brought 37:13 122:22 Buckley 97:1 Budd 3:12 5:3	budget 54:2,4,6 54:9,13 55:6,8 56:6,7,10,13 56:18,19 64:21 70:11 build 78:18 building 38:8 71:6,7 built 71:9 78:18 business 46:1,2 46:2 83:6 86:2 120:21 buy 151:19 <hr/> C <hr/> C 5:1 calculate 148:20 calculated 14:3 27:4,15 31:13 68:11 72:7 81:22 82:6 99:8,9 101:1 109:7 127:18 127:19 148:15 160:18,20 calculates 149:7 call 23:14 128:15 145:22 called 1:13 24:16 39:11,14 51:9 95:7 102:3 calls 23:11 24:5 64:6 cap 153:21 154:2,17 160:3 capacity 9:18 10:19 69:17,18 88:21 90:16 capitated 99:12 102:5 105:1 146:11,18 147:2 153:4	capitations 156:17 capped 154:4 care 7:5,7 11:3,5 11:9 15:12 17:8 18:10,15 18:22 19:13,16 20:12 21:17,21 23:2 24:7,20 25:10,12,17 69:20 71:2,3 72:4 89:10 106:2 112:17 113:3,21 114:1 114:10,17,18 114:21,22 115:1,9,11 119:6 126:7 137:4 138:14 138:22 147:12 152:18 159:2,4 Caremark 79:16,19 80:1 carried 22:18 43:4 63:11 132:20 145:18 145:20 case 6:19 7:1,4,6 7:7,9,11,13,18 102:10 107:11 159:5 cases 28:19,21 28:22 82:14 120:21 cash 111:12 cash-paying 108:1,21 109:17 110:15 111:17 112:5 112:12 catch 94:20 categories
---	---	---	---	---

Maureen Coneys

April 12, 2006

Boston, MA

4

104:13 124:18 127:15,17 category 106:4 127:21 135:12 cease 86:19 104:7 ceased 76:7 center 2:11 7:2 7:20 36:10,12 36:15 37:12,13 38:3,7,18 42:2,14 43:12 43:14 45:18 50:18 51:19 61:3 64:20 65:2 66:10,22 69:16,19 72:11 72:13 76:18 77:13,16 centers 34:17,22 35:7,13 40:10 42:9,13 43:9 43:11 48:9 50:15 51:2 53:11 61:10,12 63:15 75:19 76:21 77:8,10 79:14,19,22 80:3,7,11 106:19 107:8 107:12 108:12 108:14 center's 54:13 central 63:5 67:16 72:18 certain 12:16,17 17:22 21:13 70:13,19 71:1 93:20,20 135:12 140:17 140:17 141:12 142:2	Certified 1:16 certify 164:4,11 change 16:15 22:14 30:6,15 61:8 68:7 73:14 75:13 76:8 83:7 86:5 86:6,7,8 97:20 97:21 105:20 143:3 changed 61:9 83:20 113:17 149:6,12 150:3 154:5 changes 76:12 84:9 136:8 changing 118:7 148:19 channels 78:3 characteristics 86:16 charge 34:17,21 35:17 53:20 57:22 67:2 103:22 118:4 118:17,22 119:1 139:13 charged 108:22 111:19 146:22 151:5 152:21 153:6 charges 119:2 charge-based 118:13 charging 109:22 151:20 chats 65:5 check 57:4 Chicopee 44:5,7 Chicopee's 44:10 children 34:12	chiropractic 121:19 choice 75:17 99:16 152:19 chose 59:4 72:3 73:5 87:9 circumstances 14:6 17:3 62:18 74:2 92:11 119:15 Ciresi 1:19 2:2 5:7,20 City 3:6 Civil 1:15 claim 12:2 24:8 26:13 27:22 28:1,6 claims 11:19,21 22:9 25:21 26:1,2,8 27:8 27:13,17,19 103:18 115:5,7 115:8,8,10,15 143:13,19 clarification 162:22 clarify 56:5 123:10 157:20 clear 8:6 19:4 29:16 clinical 45:16 140:15 clinically 12:10 23:2 clinics 25:13 closed 41:7,8 closely 45:15 CMS 102:3,4 147:2 coach 121:16 coaching 159:6 Coco 2:3 5:19	5:19 17:12 19:2,7 20:21 21:5 29:14 40:22 53:1 54:19 55:3 56:16 58:15 59:5 69:6,14 71:10,18 72:8 73:20 79:4 80:9 82:13 83:22 84:11 85:5 87:15 88:10,19 91:9 100:13 102:1 105:13 106:3 108:8 110:3 111:20 112:8 112:15 117:3 117:19,22 125:12 126:1 128:20 129:4,7 129:13,17 131:18 133:11 134:7,19 136:6 137:15 138:2,6 138:19 140:13 141:11,19 142:10,16 143:15 144:17 149:2 152:6 153:2 155:5 157:3,17 158:8 158:17 159:9 160:12 162:8 162:10 code 26:12,12 28:13,16,19 coded 26:3,6 codes 29:3 coding 26:11 coinsurance 160:16	collaborate 95:14 96:1 collaboration 95:17 97:16 collaborative 68:3 95:21 96:15 97:7,14 collected 72:10 combination 70:17 combine 74:7,21 come 7:17 17:4 26:8 34:13 36:17 38:8 43:4 104:3 112:6 comes 89:16 comfortable 60:12 136:13 138:22 coming 148:6 commencing 1:21 Commission 164:22 committee 113:15 120:13 120:17,18,19 121:3,6,9,11 121:20 122:17 123:8,11,15 130:11 132:9 132:21 133:4 133:21,22 135:1,4 139:5 139:6,9 140:8 141:7 142:2 161:10,11,13 161:15 committees 12:5 committee's 133:15 134:13
--	--	--	--	--

Maureen Coneys

April 12, 2006

Boston, MA

5

135:8	complaint 91:3	6:8 53:5 68:9	34:13 36:6	99:2 104:8
common 93:13	complete 134:17	106:15 122:3,6	consumers 25:7	116:10 124:11
Commonwealth	completely 9:8	122:11 129:3	contact 23:18	125:3,6,17
1:18 164:1,4	completing 9:10	129:12,19	34:16	126:14 127:8
164:21	9:11,15	134:12 140:1	containment	135:11 147:7
communicated	complex 104:13	145:18 150:6,8	112:20	147:10 156:22
67:15	158:9	158:20 162:12	contemplated	157:2,4 158:6
communicatio...	compliance	163:13 164:5	143:7 148:19	contracts 51:5
64:14 89:18	103:7,20	conjunction	contemplation	81:2,10,13
90:14 91:11	complicated	127:2	128:18 132:20	83:2 85:8
149:16,19	136:10	consequence	133:15,22	88:16 89:1,5
community	complications	144:8	134:13	89:20 90:5
36:10,11,15	115:14	consider 18:4	content 122:14	98:21 114:8
38:17 48:8	component	123:15	context 25:8	124:20 161:7,8
50:15 51:1	66:12	consideration	119:9 131:3	contributed
61:3 80:11	comprised 12:6	16:21 94:9	137:3 145:11	73:13 105:5
106:19 108:11	73:15	122:16 135:21	158:15	control 164:8
108:13	computers	141:8 142:1	continue 85:7	convenient 53:2
companies	26:16 111:5,8	considerations	97:7 103:11	convince 155:1
33:16,21 107:9	concept 32:12	133:3 135:22	104:20,21	coordination
108:19 140:15	32:16 117:15	considered 66:4	continued 3:1	33:4,7,10,19
company 23:10	117:18 119:13	66:5 91:7	76:14 77:10	copayment
24:13 31:20	concern 136:4	126:3 132:20	continuously	160:16
35:19,21 47:22	136:16 138:4,9	135:17 137:22	8:19 10:16	copies 27:12
48:2,19 50:6,9	138:16,20	140:11 143:2	83:18 106:10	128:11
67:8 74:5,20	153:3	considering	contract 37:13	core 83:6 87:1
83:12 86:1	concerns 23:12	123:8,11	38:13,14 42:2	coronary 121:14
104:17,20	24:3	132:10,12	45:12 72:13	corporate 63:20
116:15 121:1	concluded	133:5,18	81:5 87:19	correct 24:2
124:4 135:9,13	101:12 163:7	139:17	88:14 89:9,12	25:19 29:4
139:8	conclusion	consist 40:11	98:16,19 102:2	38:19,20 39:3
company's 87:1	17:17 97:13	consisted 15:8	103:7,12	39:4,8,20
98:16 113:2,3	conclusions	consistent 29:20	104:11 108:12	42:17 43:3
114:9	18:17 127:3	consolidated	115:21 118:4	45:5 55:6 56:8
compared 14:14	128:1	63:15,16	155:10 156:6,7	57:5 64:8 66:7
comparing 18:9	condition 20:4	consolidation	157:8	70:4 72:20
21:21	conditions	63:19	contracted	73:18,22 75:8
comparison	12:17 17:22	consultant 36:3	37:15,17,21	75:12,21,22
157:7 158:1,7	115:12 136:9	consulted 32:7	38:4,7 43:8	81:9 88:15,18
comparisons	136:10 137:8	32:19 33:7	108:11	88:20 90:9
21:22	Coneys 1:13 4:3	consulting 32:4	contracting	91:5 98:5
compiling 67:20	4:9,11 5:8 6:1	32:5 33:2	80:20 87:1,5,8	100:1,12